Galmed Pharmaceuticals Ltd. buy Royal Bank of Canada
Start price
11.01.24
/
50%
€0.41
Target price
11.01.25
€63.93
Performance (%)
-31.88%
Price
24.07.24
€0.28
Summary
This prediction is currently active. Massive losses of -31.88% have been the result for the BUY prediction by Royal_Bank_of_Canada. This prediction currently runs until 11.01.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Galmed Pharmaceuticals Ltd. | 1.439% | 1.439% |
iShares Core DAX® | 0.039% | 0.567% |
iShares Nasdaq 100 | -4.018% | -5.554% |
iShares Nikkei 225® | -2.389% | -1.434% |
iShares S&P 500 | -2.115% | -2.351% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Galmed Pharmaceuticals Ltd. diskutieren
Globus Medical, Inc. (NYSE: GMED) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $70.00 price target on the stock.
Ratings data for GMED provided by MarketBeat